VITALITY-ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: study design and baseline characteristics

HARDIMAN, ORLA

doi:http://dx.doi.org/10.1080/21678421.2018.1426770

VITALITY-ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: study design and baseline characteristics

Files

VITALITY ALS a phase III trial of tirasemtiv a selective fast skeletal muscle troponin activator as a potential treatment for patients with.pdf (522.32 KB)

Date

2018

Authors

HARDIMAN, ORLA

Access

openAccess

Citation

Andrews, J.A. and Cudkowicz, M.E. and Hardiman, O. and Meng, L. and Bian, A. and Lee, J. and Wolff, A.A. and Malik, F.I. and Shefner, J.M., VITALITY-ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: study design and baseline characteristics, Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 259-266